Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2011. The report details a specific share repurchase transaction executed on February 7, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 6, 2010.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 925,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,193.5 pence per share; lowest price paid was 1,173.0 pence per share.
- Treasury Holdings (Settled): 474,194,158 shares (8.36% of total issued share capital).
- Treasury Holdings (Including Unsettled): 476,017,284 shares (9.16% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,196,535,822 shares.
Material Changes
The filing reports an increase in the Company's treasury share holdings following the purchase of 925,000 shares. Consequently, the percentage of total voting rights held in Treasury increased to 9.16% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The primary purpose is to disclose the share buyback and update the share count for regulatory notification thresholds under the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,196,535,822) for calculating disclosure thresholds.
- Confirm the current percentage of voting rights held in Treasury (9.16% including unsettled shares).
- Review the price range paid (1,173.0 to 1,193.5 pence) against market prices on February 7, 2011.
- Note that this filing does not contain operational or financial performance data.